Neuromedin U and Neuromedin S: Complete Research Profile — Anorexigenic Neuropeptides, NMUR Receptor Biology, and the Neuro-Immune Axis (2026)

# Neuromedin U and Neuromedin S: Complete Research Profile — Anorexigenic Neuropeptides, NMUR Receptor Biology, and the Neuro-Immune Axis (2026)

The neuropeptide landscape governing energy homeostasis has expanded considerably beyond the classical hypothalamic players. Among the peptides demanding closer research attention is neuromedin U (NMU) — an evolutionarily ancient, potently anorexigenic peptide whose actions span the hypothalamus, gut, stress axis, and immune system. Its more recently discovered sister peptide neuromedin S (NMS), expressed prominently in the suprachiasmatic nucleus (SCN), adds a circadian dimension to the NMU receptor system. Together, these peptides and their two receptor subtypes (NMUR1 and NMUR2) constitute a signaling axis with implications for obesity research, allergic disease, and the rapidly advancing field of neuroimmunology.

Discovery: From Uterine Smooth Muscle to Hypothalamic Control

Neuromedin U: 1985

Neuromedin U was first isolated from porcine spinal cord by Minamino and colleagues in 1985, with the name derived from its potent ability to contract uterine smooth muscle in rats (Minamino et al., Biochem Biophys Res Commun 1985;). The peptide was identified alongside neuromedin N and neuromedin B (a bombesin-related peptide) during a systematic survey of novel bioactive peptides in nervous tissue extracts.

The human neuromedin U gene (NMU) encodes a preproprotein from which proteolytic processing liberates two primary bioactive isoforms:

• •NMU-25: The full 25-amino acid form; predominant in peripheral tissues, particularly the gastrointestinal tract
• •NMU-8: The C-terminal octapeptide YFLFRPRN-NH₂; the minimal active fragment retaining full biological potency; predominant in the central nervous system

Both isoforms are C-terminally amidated — a post-translational modification essential for receptor binding. The C-terminal -FRPRN-NH₂ sequence is highly conserved across vertebrates, reflecting functional constraint across 400+ million years of evolution.

Neuromedin S: 2005

Two decades after NMU's discovery, Mori and colleagues reported a new peptide from rat brain extracts with structural similarity to NMU and overlapping receptor binding. They named it neuromedin S (NMS) and published its characterization in Nature in 2005. NMS is also C-terminally amidated and activates both NMUR1 and NMUR2 with similar potency to NMU.

Critically, NMS expression is highly enriched in the SCN — the circadian master clock — while NMU is broadly expressed in the hypothalamus and gut. This divergent expression pattern suggested that NMS connects the circadian clock to the regulatory systems governed by the NMU receptor system, a hypothesis that has since accumulated substantial experimental support.

NMUR1 and NMUR2: Receptor Biology

Receptor Subtypes and Distribution

Two G protein-coupled receptors mediate NMU/NMS signaling:

NMUR1 (NMU1R; previously FM-3):

• •Predominantly peripheral: highest expression in small intestine, colon, kidney, stomach
• •Lower-level expression in some brain regions
• •Couples to Gαq/11 → PLCβ → IP3/DAG → Ca²⁺ mobilization
• •Also couples to Gαi → inhibition of cAMP
• •Key mediator of NMU's peripheral GI effects (smooth muscle contraction, motility)

NMUR2 (NMU2R; previously FM-4):

• •Predominantly central: hypothalamus (PVN, arcuate nucleus, VMH, LH), brainstem, SCN
• •Also expressed in pituitary
• •Couples to Gαq/11 primarily
• •The primary mediator of NMU/NMS central effects on food intake, thermogenesis, and stress

The receptor subtypes were cloned and characterized by several groups in 2000, including Howard et al. (Nature 2000;), which established the pharmacological framework for the NMU system.

Signal Transduction

Both NMUR1 and NMUR2 primarily activate Gαq/11 pathways:

1. PLCβ activation → IP3 → intracellular Ca²⁺ release

2. DAG → PKC activation

3. ERK1/2 phosphorylation

4. Rho/ROCK pathway in smooth muscle contexts

In the hypothalamus, NMUR2 activation triggers rapid firing of CRF-expressing neurons in the paraventricular nucleus (PVN), connecting NMU/NMS signaling to the HPA stress axis. In ILC2s (group 2 innate lymphoid cells), NMUR1 activation triggers downstream calcium signaling that amplifies type 2 cytokine production.

Central NMU: The Anorexigenic Powerhouse

Food Intake Suppression

Central administration of NMU produces among the most potent anorexigenic effects documented in rodent models. Intracerebroventricular (ICV) injection of NMU-8 or NMU-25 reduces food intake by 50–90% in ad libitum-fed rats, with effects lasting 4–6 hours. This potency substantially exceeds that of many other anorexigenic peptides at equivalent molar doses.

The primary hypothalamic targets mediating NMU anorexigenic effects include:

• •Paraventricular nucleus (PVN): NMU activates CRF neurons, secondarily reducing food intake via the stress axis
• •Arcuate nucleus: NMU inhibits AgRP/NPY neurons (orexigenic) and may interact with POMC neurons
• •Lateral hypothalamic area (LHA): NMU modulates orexin/hypocretin neurons
• •Brainstem: NMU projections to the nucleus of the solitary tract (NTS) integrate gut satiety signals

Thermogenesis and Energy Expenditure

Beyond food intake reduction, NMU increases energy expenditure through activation of brown adipose tissue (BAT) thermogenesis. Central NMU increases:

• •Core body temperature (0.5–1.5°C elevation in rodents)
• •UCP1 expression in BAT
• •Sympathetic nervous system activity to peripheral thermogenic tissues

This dual mechanism — reducing energy intake while increasing energy expenditure — positions NMU research as directly relevant to obesity pharmacology. The thermogenic component is mediated at least partly through CRF → sympathoadrenal axis activation downstream of NMUR2 in the PVN.

NMU Knockout Phenotype

NMU-deficient mice (NMU−/−) develop obesity when maintained on standard chow — a finding that confirmed endogenous NMU as a physiological brake on adiposity. NMU−/− mice show:

• •Increased body weight and fat mass
• •Hyperphagia (elevated food intake)
• •Reduced energy expenditure
• •Impaired glucose tolerance (secondary to obesity)
• •Blunted anorexic response to fasting-refeeding

This phenotype demonstrates that endogenous NMU tone contributes meaningfully to body weight regulation, supporting the therapeutic relevance of NMUR2 agonism for obesity research.

Gut-Brain NMU Axis

Peripheral NMU in the GI Tract

NMU is one of the most abundant peptides in the gastrointestinal tract. NMU-25 is produced by enteroendocrine cells throughout the small intestine and colon, with expression highest in the upper GI tract. Peripheral NMU acts via NMUR1 on nearby smooth muscle to stimulate motility, and on enteric neurons to modulate gut neural activity.

Feeding state regulates gut NMU expression: fasting reduces intestinal NMU-25 content while refeeding restores it. This dynamic suggests that gut-derived NMU participates in postprandial signaling, potentially contributing to meal termination alongside CCK, PYY, and GLP-1.

Vagal Communication

NMU may communicate peripheral satiety signals to the hypothalamus through vagal afferents expressing NMUR1. Subdiaphragmatic vagotomy blunts the anorexigenic effects of peripheral NMU administration, implicating the vagus nerve as a key relay in the gut-to-brain NMU signaling pathway — analogous to the mechanisms described for CCK and GLP-1.

Stress Axis and HPA Integration

NMU is one of the most potent known activators of the HPA axis via central routes. ICV NMU robustly stimulates:

• •CRF release from PVN neurons
• •ACTH secretion from the anterior pituitary
• •Corticosterone (rodents) / cortisol secretion from the adrenal cortex

The NMU-stress connection extends to behavioral outputs: central NMU produces anxiety-like behaviors in the elevated plus maze and open field, reduces exploratory behavior, and increases grooming — effects consistent with CRF-mediated stress activation. NMUR2 in the PVN is the primary driver of these HPA-activating effects.

This stress-activating property of NMU is pharmacologically relevant because it suggests that while NMUR2 agonism may suppress feeding and increase thermogenesis, it may also carry anxiogenic liability through CRF pathway activation — a potential on-target side effect that must be considered in any therapeutic development context.

Circadian Biology: Neuromedin S and the SCN

Neuromedin S occupies a unique niche in the NMU receptor system due to its concentrated expression in the SCN, the master circadian oscillator. NMS expression in the SCN follows a circadian pattern with peak expression during the subjective day (light phase in nocturnal rodents).

Key NMS/circadian research findings:

• •ICV NMS administration at the onset of the light phase shifts circadian locomotor activity rhythms in rats
• •NMUR2 is expressed in SCN neurons, providing the receptor substrate for NMS autocrine/paracrine signaling within the clock
• •NMS neurons in the SCN project to the arcuate nucleus and other hypothalamic feeding centers, potentially coupling the circadian clock to the daily rhythm of food intake
• •NMS may contribute to the coupling between light-dark cycle and the daily rhythm of energy balance regulation

The NMS-SCN connection has prompted research interest in whether NMUR2-based compounds might influence circadian-metabolic coupling — a particularly relevant consideration given that circadian disruption (shift work, jet lag) is associated with metabolic syndrome and obesity.

The Neuro-Immune Axis: NMU and ILC2s

One of the most significant recent discoveries in NMU biology came not from metabolic research but from immunology. In 2017, Wallrapp and colleagues published a landmark study in Nature demonstrating that neurons expressing NMU rapidly activate ILC2s (group 2 innate lymphoid cells) via NMUR1, dramatically amplifying type 2 immune responses in the context of helminth infection and allergic inflammation (Wallrapp et al., Nature 2017;).

The Discovery

Using single-cell RNA sequencing of intestinal ILC2s, Wallrapp et al. identified NMUR1 as one of the most highly expressed neuropeptide receptors on ILC2 surface. Cholinergic enteric neurons and sensory neurons produce NMU that acts on nearby ILC2s to:

• •Potently enhance IL-5, IL-13, and amphiregulin production
• •Accelerate ILC2 proliferation
• •Lower the activation threshold for type 2 cytokine secretion in response to epithelial alarmins (IL-33, TSLP)

This neuro-immune circuit operates rapidly: within hours of helminth exposure, enteric neurons release NMU that puts ILC2s into a primed, hyperresponsive state before the adaptive immune response engages. The result is dramatically accelerated worm expulsion and type 2 immune clearance.

Implications for Allergic Disease Research

The same NMU-NMUR1-ILC2 circuit that accelerates helminth clearance may contribute to pathological type 2 inflammation in the context of allergic disease. NMUR1⁺ ILC2s are found in human lung, intestine, and skin — sites of allergic inflammation. Research is actively exploring whether:

• •NMU from sensory neurons contributes to ILC2 activation in asthma and atopic dermatitis
• •Blocking NMUR1 on ILC2s reduces allergic inflammation without impairing host defense
• •NMU levels are elevated at sites of ongoing type 2 inflammation in human allergic disease

A parallel study by Cardoso et al. (Nature 2017) and subsequent work by the Locksley group extended these findings, establishing the neuron-ILC2 axis as a fundamental feature of type 2 mucosal immunity. NMU-NMUR1 is now a validated node in this circuit.

NMU in Pain and Sensory Neurobiology

NMU is expressed in a subset of dorsal root ganglia (DRG) neurons and spinal cord interneurons. Peripheral NMU sensitizes nociceptors and enhances pain responses in inflammatory models, acting through NMUR1. Research has linked NMU to:

• •Hyperalgesia following peripheral inflammation
• •Sensitization of TRPV1-expressing nociceptors
• •Interaction with prostaglandin pathways in peripheral pain sensitization

Central NMU (spinal intrathecal) produces complex effects on nociception that depend on dose and model, mirroring the duality observed in other neuropeptide pain systems.

GLP-1 Synergy and Obesity Pharmacology Research

The ongoing revolution in GLP-1-based obesity pharmacology has renewed interest in NMU as a potential combination target. Preclinical studies have demonstrated additive or synergistic effects when NMU or NMUR2 agonists are combined with GLP-1 receptor agonists:

• •Combined NMU + GLP-1 administration produces greater food intake reduction than either peptide alone
• •The mechanisms are complementary: GLP-1 acts primarily through NTS/nodose ganglia and direct hypothalamic receptors, while NMU acts primarily through PVN CRF pathways and arcuate circuits
• •Body weight reduction in obese rodent models is greater with combination approaches

Several biotechnology companies have explored NMUR2 agonism or NMU-based fusion peptides as components of next-generation metabolic combination therapies. The challenge remains the potential anxiogenic and stress-activating liability of NMUR2 agonism through CRF pathways — a safety consideration requiring careful dose selection and monitoring in research models.

Cardiovascular and Renal Research

NMU has vasoactive properties mediated through NMUR1 in vascular smooth muscle and endothelium. Research findings include:

Vasoconstriction: NMU produces vasoconstriction in peripheral vessels, contributing to blood pressure elevation at higher central or peripheral doses.

Renal: NMUR1 is expressed in kidney tubular cells. NMU stimulates sodium reabsorption in isolated tubular preparations and may influence renal hemodynamics. The physiological significance of renal NMU signaling under normal conditions remains under investigation.

Cardiac: NMU may have cardioprotective properties in some ischemia models, though the data are less developed than for cardiovascular peptides like adrenomedullin or natriuretic peptides.

Research Tools and Pharmacology

Note: No selective NMUR1 or NMUR2 antagonists with demonstrated CNS penetrance have advanced to clinical trials as of early 2026. Receptor subtype selectivity remains an active medicinal chemistry challenge.

Current Research Landscape (2024-2026)

Active NMU research frontiers include:

Obesity combination therapy: Evaluation of NMUR2 agonists in combination with GLP-1R agonists, GIP agonists, or amylin analogs in preclinical and early clinical models.

Allergic disease neuroimmunology: Defining the NMU-NMUR1-ILC2 circuit in human allergic asthma, atopic dermatitis, and eosinophilic esophagitis. Clinical correlative studies measuring NMU levels in allergic airway inflammation.

Circadian-metabolic coupling: NMS as a SCN-derived signal linking light exposure and circadian phase to feeding behavior and energy balance.

Biased NMUR2 agonism: Developing G protein-biased NMUR2 agonists that maximize anorexigenic and thermogenic effects while minimizing CRF-mediated anxiogenic signaling through β-arrestin pathway separation.

NMU and the gut microbiome: Emerging evidence that NMU expression in enteroendocrine cells is modulated by gut microbial composition, placing NMU within the microbiome-gut-brain axis.

Conclusion

Neuromedin U and neuromedin S represent a biologically sophisticated dual-peptide system with a receptor architecture (NMUR1 peripheral, NMUR2 central) that allows coordinated regulation of energy balance from multiple anatomical vantage points. NMU is one of the most potent anorexigenic agents yet characterized, with thermogenic properties that add an energy-expenditure dimension to its anti-obesity pharmacology. The NMS-SCN axis uniquely positions this system at the circadian-metabolic interface.

The 2017 discovery that NMU is a powerful neuronal activator of ILC2-mediated type 2 immunity fundamentally expanded the NMU research agenda beyond metabolism, establishing a direct molecular link between the enteric nervous system and innate immune cell activation in allergic and anti-parasitic responses. As GLP-1-class obesity drugs reshape metabolic pharmacology, NMU/NMUR2 agonism represents one of the more biologically grounded next-generation targets — with the shared challenge of dissociating desirable metabolic effects from the anxiogenic HPA axis activation that accompanies NMUR2 stimulation.

---

References

7. Brighton PJ et al. "Neuromedin U and its receptors: structure, function, and physiological roles." Pharmacol Rev 2004;56(2):231-248. PMID: 15169928

8. Kaisho T et al. "Neuromedin U receptor 1 deficiency promotes brown adipose tissue thermogenesis." iScience 2023;26(1):105798. PMID: 36619965

10. Dodd GT et al. "Neuromedin U receptor 2 mediates the anorexic and thermogenic actions of neuromedin U in the brain." Mol Metab 2014;3(3):257-266. PMID: 24749059

---

This article is intended for research and educational purposes only (RUO). Neuromedin U, neuromedin S, and related compounds described herein are investigational research tools. No compound discussed has been evaluated by any regulatory authority for safety or efficacy in humans for the applications described. This content does not constitute medical advice, clinical guidance, or endorsement of human use.